Frazier Life Sciences Strengthens Investment Team with Addition of Lin Mu, M.D., MBA as Senior Associate

News provided by

Jan 04, 2024, 08:00 ET

PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Frazier Life Sciences (FLS), a longstanding venture capital firm investing in innovative biopharmaceuticals, proudly welcomes Lin Mu, M.D., MBA as a senior associate based in the Palo Alto office to its team of investment professionals. Lin's multidisciplinary experience spans clinical research, therapeutic commercialization, and corporate strategy. These valuable skills position him as a strong addition to FLS, enhancing the firm's capability to continue growing its venture investing.

"We believe Lin's background is ideally suited for our mission at Frazier Life Sciences. We also believe his extensive experience in management consulting, coupled with a broad foundation in clinical medicine and market development, uniquely positions him to contribute to our investment process," said Patrick Heron, managing partner at FLS. "Lin will play an important role in supporting our continued efforts to grow and evolve the Frazier Life Sciences' investment strategies."

Prior to joining Frazier, Lin was a management consultant with Boston Consulting Group's healthcare practice, where he advised biopharmaceutical clients on development and commercialization strategies. Previously, Lin was a clinical researcher at Beth Israel Deaconess Medical Center, where he supported clinical trial operations across therapeutic areas. His work has been published in top medical journals, including "The Lancet," and is widely cited in epidemiology and outcomes research.

Lin received his M.D. from Yale University, MBA from University of Cambridge, and B.S. in Biology and B.A. in Economics from Denison University.

"I am thrilled to be part of Frazier Life Sciences. Their ongoing approach of supporting talent and fostering growth made FLS an ideal team for me to join," Lin added. "I am eager to contribute to the exciting work that lies ahead, leveraging our collective experience and network to help biotech companies reach meaningful milestones."

"Lin's belief in the power of biomedical innovation and his commitment to biotech investing align with the Frazier Life Sciences investment strategies," said Anna Chen, Ph.D., principal at FLS. "I look forward to working with Lin as we connect with the broader biotech community at the upcoming 42^nd Annual JP Morgan Healthcare Conference."

About Frazier Life Sciences:
Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop and commercialize innovative biopharmaceuticals. Frazier Life Sciences' funds comprise over $3.3 billion in capital raised, including venture funds focusing on company creation and private companies, and public funds focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep experience in biopharmaceuticals, primarily located in Palo Alto, Calif. (headquarters), San Diego, Seattle, Boston, New York and London.

SOURCE Frazier Life Sciences